Casdin Capital’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Casdin Capital’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-27,407	Closed	-$2.67M	–	35
2017 Q4	$2.67M	Buy	27,407 +1,785	+7%	+$240K	0.65%	23
2017 Q3	$3.77M	Buy	25,622 +7,408	+41%	+$1.39M	1.06%	22
2017 Q2	$2.93M	Hold	18,214	–	–	1.08%	25
2017 Q1	$2.9M	Hold	18,214	–	–	1.71%	22
2016 Q4	$2.21M	Buy	18,214 +13,214	+264%	+$1.85M	1.83%	20
2016 Q3	$694K	Hold	5,000	–	–	0.56%	26
2016 Q2	$908K	Buy	+5,000	New	+$908K	0.9%	26

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Casdin Capital's SYRS Position: Q1 2018 in Review

Casdin Capital sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2018, closing a stake of 27,407 shares — an estimated $2.67M sold.

Casdin Capital first reported a position in SYRS in Q2 2016 and held it in 7 quarters. The position peaked at $3.77M in Q3 2017. 57 funds tracked by Wall St. Rank hold SYRS as of Q1 2018.

Casdin Capital reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Casdin Capital sold 27,407 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $2.67M.
Casdin Capital first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2016 and held it in 7 quarters.
Casdin Capital's Syros Pharmaceuticals, Inc. Common Stock position peaked at $3.77M in Q3 2017.
57 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on Casdin Capital's 13F filing for Q1 2018, filed 15 May 2018.